Albert W. Gianchetti
Vorstandsvorsitzender bei Xylocor Therapeutics, Inc.
Profil
Albert W.
Gianchetti is currently the President, Chief Executive Officer & Director at Xylocor Therapeutics, Inc. He previously worked as the Chief Commercial Officer & Senior Vice President at Vanda Pharmaceuticals, Inc. from 2007 to 2008 and as the Vice President-Global Commercial Strategy at GSK Plc.
He holds an MBA degree from Drexel University and an undergraduate degree from the University of Delaware.
Aktive Positionen von Albert W. Gianchetti
| Unternehmen | Position | Beginn |
|---|---|---|
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Albert W. Gianchetti
| Unternehmen | Position | Ende |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01.12.2008 |
| GSK PLC | Corporate Officer/Principal | - |
Ausbildung von Albert W. Gianchetti
| University of Delaware | Undergraduate Degree |
| Drexel University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
